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Abstract
Background: The World Health Organization has endorsed the Xpert MTB/RIF assay for investigation of patients suspected
of having tuberculosis (TB). However, its utility for routine TB screening and detection of rifampicin resistance among HIV-
infected patients with advanced immunodeficiency enrolling in antiretroviral therapy (ART) services is unknown.
Methods and Findings: Consecutive adult HIV-infected patients with no current TB diagnosis enrolling in an ART clinic in a
South African township were recruited regardless of symptoms. They were clinically characterised and invited to provide
two sputum samples at a single visit. The accuracy of the Xpert MTB/RIF assay for diagnosing TB and drug resistance was
assessed in comparison with other tests, including fluorescence smear microscopy and automated liquid culture (gold
standard) and drug susceptibility testing. Of 515 patients enrolled, 468 patients (median CD4 cell count, 171 cells/ml;
interquartile range, 102–236) produced at least one sputum sample, yielding complete sets of results from 839 samples.
Mycobacterium tuberculosis was cultured from 81 patients (TB prevalence, 17.3%). The overall sensitivity of the Xpert MTB/
RIF assay for culture-positive TB was 73.3% (specificity, 99.2%) compared to 28.0% (specificity, 100%) using smear
microscopy. All smear-positive, culture-positive disease was detected by Xpert MTB/RIF from a single sample (sensitivity,
100%), whereas the sensitivity for smear-negative, culture-positive TB was 43.4% from one sputum sample and 62.3% from
two samples. Xpert correctly identified rifampicin resistance in all four cases of multidrug-resistant TB but incorrectly
identified resistance in three other patients whose disease was confirmed to be drug sensitive by gene sequencing
(specificity, 94.1%; positive predictive value, 57%).
Conclusions: In this population of individuals at high risk of TB, intensive screening using the Xpert MTB/RIF assay increased
case detection by 45% compared with smear microscopy, strongly supporting replacement of microscopy for this
indication. However, despite the ability of the assay to rapidly detect rifampicin-resistant disease, the specificity for drug-
resistant TB was sub-optimal.
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Introduction
Tuberculosis is a major challenge for antiretroviral therapy
(ART) services in resource-limited settings where patients typically
enrol with advanced immunodeficiency [1]. Many patients
referred for ART have a current TB diagnosis, and an additional
large burden of disease is detected during pre-treatment screening
[2–4]. Tuberculosis in this population is a major cause of
morbidity and mortality [1,5–7] and presents a substantial hazard
of nosocomial disease transmission to other patients and health
care workers [8]. These risks are heightened when patients have
multidrug-resistant TB (MDR-TB) [9–11]. To address these
challenges, there is a critical need in such settings for rapid,
effective screening for TB and detection of drug resistance [1,12].
Screening for TB in this patient population is difficult, however
[12]. The World Health Organization’s (WHO) intensified case
finding symptom screen has low specificity and misses approximately
10%–20% of cases [13,14]. Sputum smear microscopy, the mainstay
of TB diagnosis in resource-limited settings, detects as few as one in
five cases when used as a screening tool pre-ART [4,12,15]. Chest
radiography is costly and not widely available; interpretation is
difficult, and up to one-third of culture-confirmed cases of pulmonary
TB diagnosed during screening have a normal radiograph [12,16].
Availability of culture-based diagnosis is also extremely limited in
resource-limited settings because of high cost and technical
complexity, and this approach often provides a diagnosis only after
several weeks [15,17]. These challenges are further compounded by
the extremely limited laboratory capacity to detect drug resistance
[18]. The threat posed by MDR-TB to efforts to control TB
worldwide [19] requires urgent improvements in diagnostic capacity.
Following a large multi-country evaluation [20], the WHO, in
December 2010, endorsed the roll-out of a novel rapid test for the
investigation of patients suspected of having TB, especially in
settings with a high prevalence of HIV-associated disease and/or
MDR-TB [21]. The Xpert MTB/RIF assay (Cepheid) is a fully
automated molecular assay in which real-time polymerase chain
reaction technology is used to simultaneously detect Mycobacterium
tuberculosis and rifampicin resistance mutations in the rpoB gene
[22,23]. The cartridge-based system dispenses with the need for
prior sputum processing and requires minimal laboratory
expertise, and results are available in less than 2 h, permitting a
specific TB diagnosis and rapid detection of rifampicin resistance.
Excellent performance characteristics were observed among
symptomatic adults with suspected TB in a large multi-country
evaluation [20]. These findings have been confirmed in a
subsequent multi-country implementation study [24] and in
several laboratory-based studies [25–29]. The assay has sensitiv-
ities of 98%–100% for smear-positive pulmonary TB, 57%–78%
for smear-negative pulmonary TB, and 53%–81% for extrapul-
monary TB when testing a variety of clinical samples [20,24–29].
Further studies are needed to examine the performance of the
assay in different clinical settings, including use as a routine screening
test to increase TB case detection in HIV-infected patients. We
evaluated the diagnostic accuracy of the Xpert MTB/RIF assay
among consecutive patients with advanced immunodeficiency being
screened for TB (regardless of symptoms) prior to starting ART in a
South African township with a very high burden of TB.
Methods
Setting
The ART cohort was based in Gugulethu township, Cape
Town, where the prevalence of HIV and the TB notification rate
are both extremely high [5]. Several studies reporting the burden,
diagnosis, and complications of TB in this cohort have previously
been published [3,5,15,16,30,31]. National TB programme
guidelines recommend investigating symptomatic adults with
suspected pulmonary TB using smear microscopy of two sputum
samples; in suspected ‘‘retreatment TB’’ cases only, culture of one
sputum sample may be requested in addition [32]. In accordance
with the national ART programme guidelines, ART was provided
for all patients with WHO stage 4 disease and/or blood CD4 cell
counts ,200 cells/ml and for pregnant women and patients with
TB with CD4 cell counts ,350 cells/ml. All patients gave written
informed consent, and this study was approved by the human
research ethics committees of the University of Cape Town and
the London School of Hygiene and Tropical Medicine. This study
conforms to the STARD initiative guidelines (http://www.stard-
statement.org/) (Text S1) for reporting of studies of diagnostic
accuracy.
Patients and Investigations
Patients eligible for the study were ART-naive, were aged
$18 y, and did not have a current TB diagnosis. Consecutive
patients referred to the clinic were prospectively recruited and
investigated at their first visit. Demographic details were recorded,
and a standardised symptom-screening questionnaire was com-
pleted. Data collected included the WHO symptom screen (one or
more of the following symptoms: current cough, fever, night
sweats, or weight loss) [14]. Two sputum samples were requested
from each patient; a spot specimen was first obtained, followed by
a second sample that was induced using nebulised 3% hypertonic
saline. If necessary, both specimens were induced. Chest
radiographs were obtained on all patients except pregnant women
and were evaluated by an experienced reader certified in the use of
the chest radiograph reading and recording system [16,33].
Radiographs were scored with regard to the presence of any
radiographic abnormality consistent with a diagnosis of TB. Blood
CD4 cell counts and plasma viral load were measured on all
patients via the routine laboratory services. For patients subse-
quently found to have false-positive Xpert MTB/RIF assays, all
clinical records at baseline and follow-up were reviewed to
determine the clinical course and ascertain any further evidence to
support or refute a TB diagnosis.
Laboratory Procedures
Sputum specimens were processed using standardised protocols
and quality assurance procedures by a centralised accredited
laboratory that participated in the previous multi-country
evaluation of the Xpert MTB/RIF assay [20]. Following
decontamination with N-acetyl-L-cysteine and sodium hydroxide,
centrifuged sputum deposits underwent microscopy, and following
resuspension in phosphate buffer, equal volumes were tested by
liquid culture and the Xpert MTB/RIF assay. The results of all
tests were read by technologists blinded to the outcomes of the
other assays. The length of time between sample collection and
results being issued to the clinic was also recorded.
Smears stained with auramine O fluorescent stain were
examined using fluorescence microscopy. Bacillary density was
graded as scanty, 1+, 2+, and 3+, and all such smears were defined
as ‘‘smear-positive’’. Sputum pellets were also tested by trained
technologists using the Xpert MTB/RIF assay as previously
described [20,22,23]. Sample reagent (1.5 ml) was added to 0.5 ml
of the resuspended sputum pellet and manually agitated twice at
room temperature during a 15-min period. The inactivated
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material was then transferred to the test cartridge and inserted into
the automated test platform, and the results were recorded.
Mycobacterial growth indicator tubes (MGITs, BD) were also
inoculated and incubated for up to 6 wk. The time to automated
growth detection was recorded. Culture isolates positive for acid-
fast bacilli were identified as M. tuberculosis complex and assessed
for genotypic resistance using the MTBDRplus assay (Hain
Lifescience). Isolates also underwent phenotypic resistance testing
for rifampicin and isoniazid by automated liquid MGIT culture
(using the modified proportion method and standard protocols).
For isolates found to have discrepant rifampicin susceptibility
results using different assays, the rpoB region was sequenced using
standard methods as previously described [20].
Definitions and Analyses
Patients with M. tuberculosis cultured from one or more sputum
samples were defined as cases of TB. Resistance to rifampicin and
isoniazid was defined by phenotypic resistance typing using MGIT
cultures wherever available; the remainder were defined by
MTBDRplus assay testing of the culture isolate.
The study population was characterised using simple descriptive
statistics, and patients with and without TB were compared using
the Wilcoxon rank-sum test, t-test, chi-square test, or Fisher’s exact
test as appropriate. Disease prevalence was determined, and
binomial regression analysis was used to identify factors associated
with TB risk. Results of MGIT culture were compared with the
results of the three other laboratory tests in a per-patient analysis.
The sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) of the assays with 95% confidence
intervals (95% CIs) were determined using Stata software. All
statistical tests were two-sided at a=0.05.
Results
Patients and TB Diagnoses
Between 12 March 2010 and 9 February 2011, 515 of 517
consecutively invited patients agreed to participate in this study. A
total of 908 samples were collected: two samples from 440 patients,
one sample from 28 patients, and no sample from 47 patients
(Figure 1). The vast majority of first sputum samples (89%) were
obtained by spontaneous expectoration, and the remainder of first
samples and all second samples were induced using hypertonic
saline. From the 908 sputum samples obtained, 28 (3.1%) cultures
were contaminated and were excluded (Figure 1). M. tuberculosis
was cultured from a total of 137 samples, resulting in TB diagnoses
in 81 patients. Of these, 67 (82.7%) were diagnosed from a first
sputum sample, and an additional 14 (17.3%) cases from a second
sample. Twenty five (30.9%) were sputum smear-positive cases for
which the highest smear grades were scanty (n=8), 1+ (n=6), 2+
(n=8), and 3+ (n=3). The median time to positivity of MGIT
cultures was 16 d (interquartile range [IQR], 11–20) overall (10 d
for smear-positive disease; 18 d for smear-negative disease).
The characteristics of the patient population are shown in
Table 1. Patients typically had advanced immunodeficiency
(median CD4 cell count, 171 cells/ml), and 26.5% of patients
had previously had TB. Compared to patients in whom no TB
diagnosis was made, TB patients had a lower body mass index,
lower CD4 cell counts, higher plasma viral loads, and more
advanced WHO stage of disease at enrolment (Table 1). A positive
WHO symptom screen was observed in 84% of TB patients (92%
for smear-positive disease and 76% for smear-negative disease)
compared to 67% of patients who were TB-free (p,0.01).
However, TB patients were not significantly more likely to report
chronic cough lasting $2 wk. Although radiological abnormalities
were more common among patients with culture-confirmed TB,
28.9% of confirmed TB patients had a normal chest radiograph
(Table 1). Conversely, 33.9% of patients who did not have TB had
an abnormal radiograph.
TB Prevalence and Risk Factors
The prevalence of culture-proven TB was 17.3% (95% CI,
13.9–20.7) among those from whom sputum could be obtained.
The prevalence rates of sputum smear-positive and smear-negative
disease were 5.3% and 12.0%, respectively. TB prevalence was
strongly associated with baseline CD4 cell count. Prevalence rates
among those with CD4 cell counts of ,100 cells/ml, ,200 cells/
ml, and .200 cells/ml were 28.1% (95% CI, 19.7–36.4), 19.4%
(95% CI, 14.7–24.0), and 13.8% (95% CI, 10.2–17.5), respective-
ly. In binomial regression analysis (Table 2), risk of TB was
independently associated with low CD4 cell count, low body mass
index, high viral load, not previously having received TB
treatment, and having a positive WHO symptom screen.
However, risk of TB was not associated with chronic cough of
$2 wk duration.
Diagnostic Accuracy of Xpert MTB/RIF for Tuberculosis
Xpert MTB/RIF assay results were obtained from 864 samples.
Tests were not done on 39 samples because of a laboratory clerical
error that was not in any way related to sputum culture outcomes
or patient status. Xpert MTB/RIF assays also gave indeterminate
results for five (0.6%) samples, which were excluded from
subsequent analyses. Of these five samples, three were culture-
positive for M. tuberculosis. A second sputum sample was available
for two of these, and Xpert MTB/RIF assays were positive in
both. Non-tuberculous mycobacteria were cultured from a total of
ten (1.1%) sputum samples from eight patients, but none of these
samples was associated with a positive Xpert MTB/RIF test.
In analyses to determine the diagnostic accuracy of Xpert
MTB/RIF for TB diagnosis, we used data from the 839 samples
from 445 patients for which results of smear microscopy, MGIT
culture, and Xpert MTB/RIF assays were all complete (Figure 1).
Analyses were first done for all patients (n=445) with results from
either one or two samples. Just over one-quarter of TB cases
(28.0%) were diagnosed using fluorescence microscopy, with
100% specificity (Table 3). In contrast, overall, 73.3% of
culture-confirmed TB cases were diagnosed using the Xpert
MTB/RIF assay, increasing case detection by 45.3% (95% CI,
32.7–57.9) compared to smear microscopy. The Xpert MTB/RIF
assay detected all smear-positive cases (100% sensitivity) and just
under two-thirds (63%) of smear-negative cases, with high
specificity (Table 3). The PPV and NPV of the Xpert MTB/
RIF assay were both 94.8% (Table 3).
A second analysis was restricted to patients with complete data
from two sputum samples (778 samples from 394 patients).
Analysis of this restricted set of data also showed that smear
microscopy performed poorly, with one and two samples yielding
just 22.2% and 26.4% of TB diagnoses, respectively, compared to
58.3% and 72.2% using the Xpert MTB/RIF assay (Table 3). The
incremental yields of using Xpert on one and two sputum samples
were 36.1% (95% CI, 23.6–48.6) and 45.8% (95% CI, 32.9–58.7),
respectively. The Xpert MTB/RIF assay also identified all cases of
smear-positive TB from a single sputum sample. Compared to the
gold standard of MGIT cultures of two samples, the diagnostic
yields of a single MGIT culture for all culture-positive, smear-
positive, and smear-negative cases were 80.6% (95% CI, 69.5–
88.9), 89.5% (95% CI, 66.9–98.7), and 77.4% (95% CI, 63.8–
87.7), respectively.
Xpert MTB/RIF Assay for TB Screening Before ART
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The sensitivity of the Xpert MTB/RIF assay for smear-negative
TB was substantially lower than for smear-positive disease and was
dependent on the number of sputum samples, with sensitivities of
43.4% and 62.3% from one and two samples, respectively. In
further analyses, factors associated with the sensitivity of the Xpert
MTB/RIF assay for smear-negative disease were explored.
Sensitivity was 100% for those with cough duration of .2 wk
compared to 56.5% (95% CI, 41.6–71.4) among those with either
no cough or cough of shorter duration (p=0.018). Moreover,
sensitivity was substantially greater in patients for whom the time
to positivity of sputum samples was less than the median of 16 d
(85.7%; 95% CI, 69.4–100) than in those with longer times to
positivity (48.5%; 95% CI, 30.4–66.5) (p=0.005). There was also a
weak association between sensitivity and CD4 cell counts:
sensitivity was 78.9% (95% CI, 58.8–99.1) in those with CD4
cell counts ,100 cells/ml compared to 54.3% (95% CI, 36.9–71.6)
in those with higher CD4 cell counts (p=0.075). However, there
was no association with radiographic abnormalities or with a
positive WHO symptom screen.
There were three patients with apparent false-positive Xpert
MTB-RIF assays, giving an assay specificity of over 99.0% in
each of the different analyses (Table 3). Review of the study and
clinical records of these patients revealed that two of these
patients had overt pulmonary and systemic symptoms suggestive
of TB, and both had chest radiographs revealing parenchymal
consolidation and marked hilar and paratracheal lymphadenop-
athy highly suggestive of TB. One of these patients was
reinvestigated during routine clinical follow-up and had two
positive sputum smears (2+ and 3+). Both patients received
standard treatment for TB and made excellent clinical responses.
The third patient had symptoms and an abnormal chest
radiograph but was lost to follow-up.
Figure 1. Flow diagram showing the numbers of patients enrolled, losses, numbers of sputum samples analysed, and numbers of
results obtained.
doi:10.1371/journal.pmed.1001067.g001
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Table 1. Characteristics of all patients (n= 468) for whom results of sputum cultures were available from one or more sputum
samples.
Patient Characteristicsa
All Patients
(n=468)
TB Diagnosed
(n=81)
No TB Diagnosed
(n=387) p-Valueb
Age, median (IQR) 33.6 (27.8–40.7) 32.1 (28.2–40.4) 33.6 (27.7–40.8) 0.70
Female 306 (65.4%) 54 (66.7%) 252 (65.1%) 0.79
BMI, median (IQR) 23.5 (20.9–27.2) 21.4 (19.1–25.9) 23.9 (21.1–27.6) ,0.001
History of previous TB 124 (26.5%) 16 (19.8%) 108 (27.9%) 0.13
CD4 cell counts (cells/ml)
Median (IQR) 171 (102–236) 130.5 (51.5–206.6) 176 (112–243) ,0.001
CD4 ,50 59 (12.6%) 20 (24.7%) 39 (10.1%) 0.006
CD4 50–99 55 (11.8%) 12 (14.8%) 43 (11.1%)
CD4 100–149 90 (19.2%) 15 (18.5%) 75 (19.2%)
CD4 150–199 85 (18.2%) 9 (11.1%) 76 (19.6%)
CD4 $200 179 (38.3%) 25 (30.9%) 154 (39.9%)
Baseline viral load, median (IQR) (log10 copies/ml) 4.5 (4.0–5.0) 4.8 (4.4–5.3) 4.5 (4.0–4.9) ,0.001
WHO stage at enrolment
1 or 2 317 (67.7%) 45 (55.6%) 272 (70.3%) 0.009
3 or 4 151 (32.3%) 36 (44.4%) 115 (29.7%)
Positive WHO symptom screen 328 (70.1%) 68 (84.0%) 260 (67.2%) 0.003
Current cough $2 wk 103 (22.0%) 22 (27.2%) 81 (20.9%) 0.22
Radiological abnormality consistent with TBc 170 (40.7%) 54 (71.1%) 116 (33.9%) ,0.001
aData are number of patients (percent) unless otherwise indicated.
bComparison of characteristics of patients with and without TB.
cChest radiographs available for 418 patients.
doi:10.1371/journal.pmed.1001067.t001
Table 2. Binomial regression analysis showing crude and adjusted risk ratios for the associations between risk of sputum culture-
positive tuberculosis and patient characteristics.
Patient Characteristics
Crude Risk
Ratio 95% CI p-Value
Adjusted Risk
Ratio 95% CI p-Value
Age #30 y 1
Age .30 y 0.90 0.61–1.34 0.62
Male 1
Female 1.06 0.70–1.61 0.79
Body mass index 18–25 kg/m2 1 1
Body mass index ,18 kg/m2 2.32 1.44–3.75 0.001 2.94 1.30–6.63 0.009
Body mass index .25 kg/m2 0.68 0.42–1.09 0.109 0.70 0.39–1.27 0.243
No history of previous TB treatment 1 1
History of previous TB treatment 0.68 0.41–1.13 0.14 0.50 0.26–0.96 0.036
CD4 $100 cells/ml 1 1
CD4 ,100 cells/ml 2.08 1.41–3.08 ,0.001 2.01 1.17–3.45 0.011
Viral load ,4.5 log copies/ml 1 1
Viral load $4.5 log copies/ml 2.29 1.46–3.59 ,0.001 2.12 1.22–3.69 0.008
No cough $2 wk 1
Cough $2 wk 1.32 0.85–2.05 0.21
Negative symptom screen 1 1
Positive symptom screen 2.23 1.28–3.90 0.005 2.35 1.22–4.50 0.010
doi:10.1371/journal.pmed.1001067.t002
Xpert MTB/RIF Assay for TB Screening Before ART
PLoS Medicine | www.plosmedicine.org 5 July 2011 | Volume 8 | Issue 7 | e1001067
Use of Xpert MTB/RIF in Screening Algorithms
To further explore the utility of the Xpert MTB/RIF assay, we
considered clinical populations with a TB prevalence of 20%, 15%,
10%, or 5%. With an overall sensitivity of 73.3% and specificity of
99.2% (Table 3), the PPVs at these TB prevalence rates would be
95.8%, 94.2%, 91.0%, and 82.8%, respectively, and the NPVs
would be 93.7%, 95.5%, 97.1%, and 98.6%, respectively.
We next considered the utility of incorporating the Xpert
MTB/RIF assay into different screening algorithms, examining
the use of smear microscopy, symptom screening, one Xpert assay,
two Xpert assays (Xpert done on a second sample if the first was
negative), and sequential smear microscopy and Xpert testing
(Xpert tests done if smear microscopy was negative). This was
simulated for a hypothetical cohort of 1,000 patients with a TB
prevalence of 20%, 15%, 10%, or 5% and assuming that 30% of
cases were smear-positive. Symptom frequencies and the sensitiv-
ity and specificity of the Xpert assay as reported above were used.
The yield of TB cases, the number of missed cases, and the
number of Xpert tests done for each correct TB diagnosis were
compared between these different screening strategies and clinical
populations (Table 4). Compared to a base case scenario of smear
microscopy of two sputum samples in patients with a positive
WHO symptom screen, the sensitivity of algorithms incorporating
the Xpert MTB/RIF assay was much greater and the corre-
sponding number of missed diagnoses was far fewer. However, at a
TB prevalence of 5%, the number of Xpert tests done per case
diagnosed was high (Table 4). A strategy of sequential smear
microscopy and then Xpert testing of smear-negative patients
yielded the same number of diagnoses, but did not substantially
reduce the number of Xpert tests per case diagnosed.
Use of symptom pre-screening limited the sensitivity of TB
detection. In populations with high TB prevalence, Xpert testing
of all patients regardless of symptoms increased sensitivity without
substantially increasing the number of Xpert tests done per TB
case diagnosed (Table 4). Compared to the strategy of doing an
Xpert assay on one sputum sample from patients with a positive
symptom screen, a strategy of doing two Xpert tests on all patients
was associated with 22.9% higher sensitivity for TB and the fewest
missed cases. Although the latter strategy would require a large
absolute number of tests, at a TB prevalence of 20%, one extra TB
case would be diagnosed for every additional 6.3 tests done.
Detection of Rifampicin Resistance
Among 81 cases of TB diagnosed, four cases had isolates
resistant to rifampicin because of MDR-TB (prevalence, 4.9%;
95% CI, 1.4–12.2). Among the 445 patients (839 samples) with
results of culture, drug susceptibility testing, and Xpert MTB/RIF
assays all available, there were 84 isolates from 55 patients
(including all four cases of MDR-TB) in which rifampicin
susceptibility could be compared. Rifampicin resistance was
correctly identified in all four cases of MDR-TB by the Xpert
MTB/RIF assay (100% sensitivity) (Table 5). However, the Xpert
MTB/RIF assay also reported rifampicin resistance in three
samples from three further patients in which the isolates were
reported as rifampicin susceptible using comparator assays
(Table 5). A paired sputum sample was available from two of
these patients and rifampicin-susceptible M. tuberculosis was
reported by Xpert MTB/RIF assay in both. To resolve these
discrepancies, the rpoB regions of all five isolates from these three
patients were sequenced. All were found to be wild-type,
confirming absence of genotypic rifampicin resistance and
indicating that the three Xpert MTB/RIF assay results were false
positives. All remaining patients with susceptible isolates were
correctly identified as such by the assay. Thus, in a per-patientT
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analysis, the PPV of the Xpert MTB/RIF assay for detecting
rifampicin resistance was 4/7 (57%) and the specificity was 48/51
(94.1%; 95% CI, 84.8–98.8).
Time to Diagnosis
The median delays between sputum collection and results being
available to the clinic for smear microscopy and Xpert MTB/RIF
assays and positive liquid cultures were 3 d (IQR, 2–5) and 4 d
(IQR, 3–6), respectively. The median delays for culture results
were 12 d (IQR, 10–14) and 20 d (IQR, 17–27) for smear-positive
and smear-negative disease, respectively. Cultures were incubated
for 42 d before being declared negative for M. tuberculosis, with a
median time to reporting of 43 d (IQR, 43–45). For the patients
with confirmed MDR-TB (n=4), the mean time to TB diagnosis
and detection of rifampicin resistance was 2 d using Xpert MTB/
RIF assay, 21 d using the MTBDRplus assay on a positive culture
isolate, and 40 d using phenotypic drug susceptibility testing in
liquid culture.
Discussion
A high prevalence (17.3%) of culture-proven pulmonary TB was
diagnosed in this patient population, but conventional diagnostic
tools widely used in resource-limited settings performed poorly.
Smear microscopy detected just 28% of cases, and chest radiology
was of low discriminatory value. Even using automated liquid
culture as the diagnostic gold standard, diagnosis was slow, with a
median delay of almost 3 wk among those with smear-negative
disease. In contrast, the Xpert MTB/RIF assay was able to
diagnose with extremely high specificity all cases of smear-positive
TB and almost two-thirds of smear-negative cases and three-
quarters of cases overall when testing two samples. Only 0.6% of
test results were indeterminate. The assay also rapidly detected
rifampicin resistance in all four cases of confirmed MDR-TB.
However, false-positive rifampicin resistance results were also
observed.
The TB prevalence and associated risk factors detected in this
clinical setting were similar to those previously reported from this
and another ART clinic in South Africa [3,4,15]. Almost 30% of
patients with CD4 cell counts ,100 cells/ml had culture-proven
TB, and rapid diagnosis is needed since such patients have high
mortality risk [5,34]. Only one-quarter of all TB patients reported
a cough lasting $2 wk—a symptom screen widely used for many
years to define suspected TB cases. Use of the new WHO
symptom screening tool [13,14] had higher sensitivity but still
would have missed 13 of the 81 TB diagnoses made in this study,
suggesting the need for routine microbiological screening of all
patients in this setting.
We evaluated the utility of the Xpert MTB/RIF assay as a
screening tool in consecutive HIV-infected adult patients enrolling
for ART, excluding those who already had a TB diagnosis
(approximately one-third of referrals to this cohort [35]). Since
patients were screened regardless of the presence or absence of
symptoms, our study is likely to have diagnosed TB cases at an
earlier stage in the disease course than studies in which
symptomatic patients were tested. In contrast, the previous
Foundation for Innovative New Diagnostics multi-country evalu-
ation [20] enrolled only patients with overt TB symptoms; all had
a chronic cough of at least 2 wk duration and were able to produce
three 1.5-ml sputum specimens. Early disease in our study would
tend to be associated with lower bacillary numbers in sputum
samples, as indicated by the observations that almost 70% of cases
were sputum smear-negative and the prolonged median time to
positivity of liquid cultures. This patient population therefore
represents a major challenge for any diagnostic assay [17]. The
limits of detection of the Xpert MTB/RIF assay (95% sensitivity)
defined by in vitro experiments is 131 bacilli/ml of sputum, which
approaches than that of liquid culture, which falls within the range
10–100 bacilli/ml [17,23]. In contrast, smear microscopy is able to
detect only samples with more than approximately 10,000
organisms per millilitre [17,23].
Testing a single sputum sample using Xpert MTB/RIF allowed
diagnosis of all smear-positive cases regardless of smear grade;
these cases pose the greatest infectious hazard within the
community and health care settings. As anticipated [17], the
sensitivity for smear-negative disease was lower than that reported
in the previous multi-country evaluation [20] (43.3% versus 72.5%
using one sputum sample; 63.3% versus 85.1% using two samples).
Presence of cough of $2 wk was associated with much higher
sensitivity for smear-negative TB, as was shorter time to culture
positivity. The latter observation suggests that sensitivity was likely
to have been limited by very low numbers of bacilli in sputum
samples.
Three patients had false-positive TB diagnoses using Xpert
MTB/RIF compared to the predefined laboratory gold standard
of liquid culture. However, the clinical and radiological features in
Table 5. Comparison of results regarding drug susceptibility testing for rifampicin among paired samples from patients (n= 6) in
whom rifampicin resistance was detected using one or more assays.
Patient
Number
Sputum
Smear
Xpert
MTB/RIF
MTBDRplus
on Sputum
MTBDRplus
on Culture
Isolate
MGIT
Phenotypic
DST
rpoB Gene
Sequencing
Final Rifampicin
Susceptibility
Overall
Susceptibility
Pattern
Concordant susceptibility results
#020 NEG/NEG 2/R 2/2 2/R 2/R 2 Resistant MDR-TB
#099 POS/POS R/R 2/R R/R 2/2 2 Resistant MDR-TB
#208 NEG/NEG R/2 2/2 R/R R/R 2 Resistant MDR-TB
#292 NEG/POS R/R R/2 R/R R/2 2 Resistant MDR-TB
Discordant susceptibility results
#039 NEG/NEG R/S S/2 S/S S/S WT/WT Susceptible Pan-susceptible
#157 POS/POS R/S S/S S/S S/S WT/WT Susceptible Pan-susceptible
#322 POS R 2 S S WT/WT Susceptible Pan-susceptible
DST, drug susceptibility testing; NEG, smear-negative; POS, smear-positive; R, resistant; S, susceptible; WT, genotypically wild-type.
doi:10.1371/journal.pmed.1001067.t005
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these cases were highly suggestive of TB; one was confirmed as
having smear-positive TB on reinvestigation, two exhibited
excellent responses to TB treatment, and the third patient was
lost to follow-up. These follow-up data suggest that some or all of
these false-positive Xpert MTB/RIF assays may actually have
been correct. The proportion of cultures lost to contamination was
very low (3.1%), highlighting possible over-decontamination in the
laboratory and loss of sensitivity in the culture gold standard. If
this was the case, the PPV of the assay would be higher, which
would increase assay utility, especially in clinical populations with
lower disease prevalence. Few Xpert MTB/RIF assays were
indeterminate, but the observation that three out of five of these
were in culture-positive cases suggests that indeterminate results
should be followed up by a repeat test.
Despite only moderate sensitivity for smear-negative disease,
Xpert MTB/RIF nevertheless increased overall case detection by
36% when testing one sample and by 45% when testing two
samples, compared to smear microscopy. Used for baseline
screening evaluation of patients enrolling in this ART service,
Xpert MTB/RIF testing of a single sputum sample would detect
TB in approximately 10% of the cohort, and testing two samples
would detect TB in 12.5%. Thus, the assay would detect
approximately one TB case for every eight patients screened,
compared to one in 18 patients screened using sputum
microscopy.
We explored the potential impact of incorporating the assay in
several screening algorithms applied to clinical populations with a
range of TB prevalence rates. The likely benefits (increased TB
yield) and assay costs (tests done per case diagnosed) were highly
dependent on TB prevalence, and at a prevalence rate of 5%, the
number of tests done per case diagnosed was high (4-fold higher
than for a population with a prevalence of 20%). A strategy of
screening with sputum microscopy and then testing smear-
negative samples with Xpert MTB/RIF assay would result in
minimal savings with regard to the number of Xpert tests done but
would also result in failure to diagnose MDR-TB in highly
infectious smear-positive cases. Symptom pre-screening restricted
sensitivity and, at higher TB prevalence rates, did not substantially
reduce the number of Xpert MTB/RIF tests done to identify one
case of TB when compared to a strategy of testing all patients
regardless of symptoms. Screening two samples with Xpert MTB/
RIF would substantially increase the absolute number of tests
done, but at high TB prevalence rates the high incremental yield
may justify this approach. The number of Xpert MTB/RIF assays
done might logically be stratified by CD4 cell count since this is a
strong predictor of TB prevalence. For example, in high-burden
settings such as South Africa, two tests might be done for those
with CD4 cell count ,200 cells/ml and just one test for those with
higher counts. These strategies need to be evaluated by detailed
cost-effectiveness analyses that take into account not simply the
costs of testing but also the downstream impact on clinical
outcomes and associated costs.
Since the Xpert MTB/RIF instrument was based in a
centralised laboratory service, with results reported via the routine
laboratory system, the median time to diagnosis was similar to that
of smear microscopy (4 d versus 3 d, respectively). The time to
diagnosis of smear-negative disease, however, was shortened by a
median of 2 wk compared to culture. Time to diagnosis and
treatment would potentially be further shortened by location of the
instrument in the ART clinic [24]. The assay also has the potential
to shorten the time to exclude a diagnosis of TB; this normally
takes 6 wk or more via negative cultures and may lead to
inappropriate delays in ART initiation. In view of the high NPV of
the Xpert MTB/RIF assay in this cohort (94.8%), a negative result
at baseline evaluation could provide a useful indication of a low
probability of TB, increasing clinical confidence to start ART
without undue delay. In cohorts with a lower prevalence of TB,
the NPV would be higher, further increasing its utility in this
regard.
HIV-associated MDR-TB carries a high mortality risk, and
nosocomial outbreaks in HIV care and treatment centres pose a
grave threat to patients accessing these services [9,10,36]. Many
patients with HIV-associated MDR-TB die before a diagnosis can
be made [9,36]. In this study, the Xpert MTB/RIF assay
identified four patients with rifampicin-resistant isolates who had
MDR-TB, greatly reducing the mean time to detection (2 d)
compared to using conventional culture-based susceptibility testing
(40 d) or using line probe assays on culture isolates (20 d). By
accelerating diagnosis, the Xpert MTB/RIF assay has the
potential to substantially reduce the risks of nosocomial transmis-
sion of MDR-TB and improve the prognosis of affected
individuals.
The Xpert MTB/RIF assay reported three false-positive
rifampicin resistance results. The finding of discordant rifampicin
susceptibility results from paired samples using the Xpert MTB/
RIF assay suggests that specificity might be increased by requiring
confirmation of resistance in more than one sample. While such
false positives were not found in the initial multi-country
evaluation [20], another ongoing field study sponsored by the
Foundation for Innovative New Diagnostics has also detected
cases, leading the manufacturer to modify the instrument software
and cartridge specifications [24,37]. With WHO approval of roll-
out of this assay in December 2010, confirmation of successful
reconfiguration of the test platform is urgently required.
Strengths of the study include the use of a quality-assured
laboratory that participated in the previous multi-country
evaluation [20]. Whereas all previously published studies have
evaluated use of the assay among individuals with suspected TB
[20,24–29], this study evaluated the assay as a screening tool in
unselected consecutive patients regardless of symptoms in a high-
burden setting. The TB status of all patients was clearly defined
based on a rigorous laboratory gold standard. Weaknesses include
the fact that a small number of tests were not done because of a
laboratory clerical error and that there were few cases of MDR-
TB. While a similar burden of disease has been reported from an
ART clinic elsewhere in South Africa [4], the prevalence of TB
may differ in other countries, and we therefore explored utility at a
range of prevalence rates. The impact of the sputum concentration
procedure and of dividing the sputum pellet between three assays
rather than testing unprocessed sputum was not investigated in this
study, but these methods were not found to impact assay sensitivity
in a previous large-scale multi-country evaluation [20]. The
usefulness of the assay as a point-of-care test was not evaluated.
Further studies are needed to assess the impact of Xpert MTB/
RIF screening on subsequent patient outcomes, the operational
feasibility of using the assay within the clinic, and cost-
effectiveness.
In conclusion, when used as a routine screening test among
patients with advanced immunodeficiency and high TB risk, rapid
screening using the Xpert MTB/RIF assay substantially increased
case detection, supporting replacement of microscopy as the initial
diagnostic tool. The assay also greatly decreased the time to
diagnosis of MDR-TB. Use of Xpert MTB/RIF as a screening
tool might effectively reduce the risk of nosocomial MDR-TB
outbreaks in HIV care and treatment settings and improve the
prognosis of affected patients. However, the specificity of the assay
for detecting rifampicin resistance needs to be improved to prevent
overdiagnosis of rifampicin-resistant disease.
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Editors’ Summary
Background. Tuberculosis (TB)—a contagious bacterial
infection that mainly affects the lungs—is a leading cause
of illness and death among people who are infected with
HIV, the virus that causes AIDS by destroying the immune
system, which leaves infected individuals susceptible to
other infections. TB is caused by Mycobacterium tuberculosis,
which is spread in airborne droplets when people with the
disease cough or sneeze. Its symptoms include a persistent
cough, weight loss, and night sweats. Diagnostic tests for TB
include chest X-rays, sputum smear analysis (microscopic
examination of mucus coughed up from the lungs for M.
tuberculosis bacilli), and mycobacterial liquid culture (the
growth of M. tuberculosis from sputum and determination of
its drug sensitivity). TB can be cured by taking several drugs
daily for six months, although the recent emergence of
multidrug-resistant TB (MDR-TB) is making the disease
increasingly hard to treat.
Why Was This Study Done? TB is a major problem in
clinics that provide antiretroviral therapy (ART) for HIV-
positive people in resource-limited settings. Not only is it a
major cause of sickness and mortality in those affected by it,
but TB (especially MDR-TB) can also spread to other patients
attending the same clinic for health services. Rapid diagnosis
and appropriate treatment are very important to reduce
these risks. Unfortunately, sputum smear analysis—the
mainstay of TB diagnosis in resource-limited settings—only
detects about a fifth of TB cases when used as a screening
tool before initiating ART. Chest X-rays are costly and don’t
always detect TB, and liquid culture—the gold standard
method for TB diagnosis—is costly, technically difficult, and
slow. Consequently, the World Health Organization (WHO)
recently endorsed a new test for the investigation of patients
suspected of having TB, especially in regions where HIV
infection and MDR-TB are common. Xpert MTB/RIF is an
automated DNA test that detects M. tuberculosis and DNA
differences that make the bacteria resistant to the drug
rifampicin (an indicator of MDR-TB) within 2 hours. In this
study, the researchers investigate whether Xpert MTB/RIF
could be used as a routine screening test to increase TB
detection among HIV-positive people initiating ART.
What Did the Researchers Do and Find? The researchers
collected sputum from HIV-infected adults with no current
TB diagnosis enrolling at an ART clinic in a South African
township where HIV infection and TB are both common.
They then compared the diagnostic accuracy of Xpert MTB/
RIF (performed at a centralized laboratory) with that of
several other tests, including liquid culture (the reference
test). Nearly a fifth of the patients had culture-positive TB.
Xpert MTB/RIF identified three-quarters of these patients (a
sensitivity of 73.3%). By contrast, the sensitivity of smear
microscopy was 28%. The new test’s specificity (the
proportion of patients with a negative Xpert MTB/RIF result
among patients without TB) was 99.2%. That is, Xpert MTB/
RIF had a low false-positive rate. Notably, Xpert MTB/RIF
detected all cases of smear-positive, culture-positive TB but
only 43.4% of smear-negative, culture-positive cases from a
single sputum sample; it detected 62.3% of such cases when
two sputum samples were analyzed. Finally, Xpert MTB/RIF
correctly identified rifampicin resistance in all four patients
who had MDR-TB but incorrectly identified resistance in
three patients with drug-sensitive TB.
What Do These Findings Mean? In this population of
HIV-positive patients with a high TB risk, pre-ART screening
with Xpert MTB/RIF increased case detection by 45%
compared to smear microscopy, a finding that needs
confirming in other settings. Importantly, Xpert MTB/RIF
reduced the delay in diagnosis of TB from more than 20 days
to two days. This delay would be reduced further by doing
the assay at ART clinics rather than at a centralized testing
facility, but the diagnostic accuracy of point-of-care testing
needs evaluating. Overall, these findings (and those of an
accompanying article by Scott et al. that examines the
performance of Xpert MTB/RIF in an area where HIV infection
is common) support the replacement of smear microscopy
with Xpert MTB/RIF for pre-ART TB screening (provided
misdiagnosis of rifampicin resistance can be reduced). These
findings also suggest that routine screening with Xpert MTB/
RIF could reduce the risk of MDR-TB outbreaks in HIV care
and treatment settings and improve outcomes for HIV-
positive patients with MDR-TB who currently often die
before a diagnosis of TB can be made.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001056.
N This study is further discussed in a PLoS Medicine
Perspective by Carlton Evans; a related PLoS Medicine
Research Article by Scott et al. is also available
N WHO provides information (in several languages) on all
aspects of tuberculosis, including general information on
tuberculosis diagnostics and specific information on the
Xpert MTB/RIF test; further information about WHO’s
endorsement of Xpert MTB/RIF is included in a recent
Strategic and Technical Advisory Group for Tuberculosis
report
N WHO also provides information about tuberculosis and HIV
N The US National Institute of Allergy and Infectious Diseases
has detailed information on tuberculosis and HIV/AIDS
N The US Centers for Disease Control and Prevention also has
information about tuberculosis, including information on
the diagnosis of and on tuberculosis and HIV co-infection
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on HIV-related tuberculosis (in English and Spanish)
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